CHA Biotech Co. Ltd
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising f… Read more
CHA Biotech Co. Ltd (085660) - Total Liabilities
Latest total liabilities as of September 2025: ₩1.57 Trillion KRW
Based on the latest financial reports, CHA Biotech Co. Ltd (085660) has total liabilities worth ₩1.57 Trillion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CHA Biotech Co. Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how CHA Biotech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CHA Biotech Co. Ltd Competitors by Total Liabilities
The table below lists competitors of CHA Biotech Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fujian Longxi Bearing Group Co Ltd
SHG:600592
|
China | CN¥850.66 Million |
|
PT Indosat Tbk
PINK:PTITF
|
USA | $81.26 Trillion |
|
Keboda Technology Co Ltd
SHG:603786
|
China | CN¥2.62 Billion |
|
TV Asahi Holdings Corporation
PINK:THDDY
|
USA | $109.37 Billion |
|
Hefei Urban Construction Development Co Ltd
SHE:002208
|
China | CN¥26.75 Billion |
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
USA | $21.34 Million |
|
SANGETSU CO LTD
OTCGREY:SGSUF
|
USA | $70.08 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down CHA Biotech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CHA Biotech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CHA Biotech Co. Ltd (2008–2024)
The table below shows the annual total liabilities of CHA Biotech Co. Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩1.91 Trillion | +78.60% |
| 2023-12-31 | ₩1.07 Trillion | -18.71% |
| 2022-12-31 | ₩1.32 Trillion | +21.89% |
| 2021-12-31 | ₩1.08 Trillion | +12.57% |
| 2020-12-31 | ₩958.62 Billion | +22.00% |
| 2019-12-31 | ₩785.74 Billion | +26.62% |
| 2018-12-31 | ₩620.54 Billion | +10.25% |
| 2017-12-31 | ₩562.87 Billion | +16.63% |
| 2016-12-31 | ₩482.61 Billion | +36.05% |
| 2015-12-31 | ₩354.73 Billion | +93.39% |
| 2014-12-31 | ₩183.43 Billion | +5.96% |
| 2013-12-31 | ₩173.12 Billion | -7.45% |
| 2012-12-31 | ₩187.06 Billion | -1.32% |
| 2011-12-31 | ₩189.56 Billion | +7.67% |
| 2010-12-31 | ₩176.06 Billion | +71.36% |
| 2009-12-31 | ₩102.75 Billion | +402.00% |
| 2008-12-31 | ₩20.47 Billion | -- |